**Core Concept**
The question pertains to the use of a specific monoclonal antibody for immunosuppression in organ transplant patients. CD25 is a subunit of the high-affinity IL-2 receptor, and targeting this receptor can modulate the immune response. The anti-CD25 humanized monoclonal antibody is designed to block IL-2 signaling, thereby reducing T-cell proliferation and activation.

**Why the Correct Answer is Right**
The anti-CD25 humanized monoclonal antibody is Basiliximab. Basiliximab works by binding to the CD25 subunit of the IL-2 receptor, preventing IL-2 from interacting with its receptor and subsequently inhibiting T-cell activation and proliferation. This mechanism of action results in reduced immune response and inflammation, making it an effective immunosuppressive agent in organ transplant patients.

**Why Each Wrong Option is Incorrect**
**Option A:** There is no widely used anti-CD25 monoclonal antibody called "Daclizumab" (which is actually a different monoclonal antibody targeting CD25).
**Option B:** Muromonab-CD3 is a monoclonal antibody targeting the CD3 receptor on T-cells, not CD25.
**Option C:** Mycophenolate mofetil is an immunosuppressive drug that works by inhibiting inosine monophosphate dehydrogenase, not by targeting CD25.
**Option D:** There is no specific anti-CD25 monoclonal antibody called "Tocilizumab" (which targets IL-6 receptor).

**Clinical Pearl / High-Yield Fact**
Basiliximab is used to prevent acute rejection in kidney transplant patients and is typically administered on two separate occasions, 14 days apart. This timing is crucial to maximize its immunosuppressive effects.

**Correct Answer:** D. Basiliximab